Clinical trial results announced at the Transcatheter Therapeutics conference in San Francisco headlined the medtech research and development news last week. Noteworthy "commercial" developments in late October include iCad’s decision to sell its Xoft brachytherapy business to Elekta and Butterfly Network's plans to work with Forest Neurotech on brain-computer interfaces.

Plus deals involving BioLineRx/GloriaBio, Healios/Athersys, Aurobindo/Hilleman, Lupin/Menarini, GC Biopharma/Immetas, CanariaBio, Specialised Therapeutics, TaiGen/Y.S.P., Nippon/Kayaku/Adlai Nortye, WuXi/PharmaEssentia, Evommune/Maruho and Ono/Adimab.

National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.